Lachira-Yparraguirre L, Al-kassab-Córdova A, Quispe-Silvestre E, Enriquez-Vera D

Language: Spanish
References: 19
Page:
PDF size: 390.76 Kb.

ABSTRACT

Introduction: Waldenström's macroglobulinemia is a hematological neoplasm belonging to the group of monoclonal gammopathies, which includes systemic symptoms and those related to an increase in M paraprotein.
Objective: To describe a case of cardiac amyloidosis associated with macroglobulinemia.
Clinical case: Male patient who was admitted for asthenia, dysphonia, and who, during his evolution, developed progressive dyspnea, heart failure and pleural effusion. Additionally, echocardiography showed myocardial granular pattern, while pleural biopsy was positive for Congo red staining. Subsequently, he received treatment with bortezomib, dexamethasone and rituximab, with favorable evolution.
Conclusions: In this disease, early diagnosis is an important advantage for survival. Therefore, its management is palliative of cardiac manifestations. The present case shows a diagnostic challenge, in which the less frequent etiologies of heart failure must be taken into account.

REFERENCES

1. Swerdlow SH, Cook JR, Sohani AR, Pileri SA, Harris NL, Jaffe ES, et al. Lymphoplasmacytic lymphoma. En: Kleihues P, coordinador. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 232-5.

2. Wang H, Chen Y, Li F, Delasalle K, Wang J, Alexanian R, et al. Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: a large population-based study. Cancer. 2012 Ago;118(15):3793-800.

3. Cardemil D, León P, Peña C, Valladares X, Cabrera ME. Macroglobulinemia de Waldenström. Experiencia de 15 años en el Hospital del Salvador, Santiago, Chile. Rev méd Chile. 2019;147(3):275-80.

4. Munshi N, Longo D, Anderson K. Capítulo 107: Trastorno de Células Plasmáticas. Harrison's Principles of Internal Medicine. 20th ed. New York: McGraw-Hill; 2019.

5. Yun S, Johnson AC, Okolo ON, Arnold SJ, McBride A, Zhang L, et al. Waldenström Macroglobulinemia: Review of Pathogenesis and Management. Clin Lymphoma Myeloma Leuk. 2017 May;17(5):252-62.

6. García-Sanz R, Montoto S, Torrequebrada A, de Coca AG, Petit J, Sureda A, et al. Waldenström macroglobulinemia: presenting features and outcome in a series with 217 cases. Br J Haematol. 2001 Dec;115(3):575-82.

7. Zhang C, Huang X, Li J. Light chain amyloidosis: Where are the light chains from and how they play their pathogenic role?. Blood Rev. 2017 Jul;31(4):261-70.

8. Gertz MA, Sher T, Dispenzieri A, Buadi FK. Chapter 108: Immunoglobulin Light-Chain Amyloidosis. Williams Hematology. 9thed. New York: McGraw-Hill Medical; 2016.

9. Ruiz-Mori E, Ayala-Bustamante L, Taxa-Rojas L, Pacheco-Román C, Alarcón-Santos J, Burgos-Bustamante J. Cardiac amyloidosis: a case report. Horiz Med. 2018;18(4):81-9.

10. Singh A, Geller HI, Alexander KM, Padera RF, Mitchell RN, Dorbala S, et al. True, true unrelated? Coexistence of Waldenström macroglobulinemia and cardiac transthyretin amyloidosis. Haematologica. 2018 Aug;103(8):e374-e376.

11. Muchtar E, Dispenzieri A, Lacy MQ, Buadi FK, Kapoor P, Hayman SR, et al. Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition. Ann Med. 2017 Nov;49(7):545-51.

12. Kholova I, Niessen HWM. Amyloid in the cardiovascular system : a review. J Clin Pathol. 2005 Feb;58(2):125-33.

13. Lousada I, Comenzo RL, Landau H, Guthrie S, Merlini G. Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium. Adv Ther. 2015 Oct; 32(10):920-8.

14. Jacob A, Raj R, Walkow W. Systemic Amyloidosis and Cardiac Autonomic Neuropathy Associated with Waldenstrom's Macroglobulinemia. Case Rep Hematol 2017;2017:8795213. doi: 10.1155/2017/8795213

15. Romaní F, Cuadra J, Atencia F, Canelo C. Macroglobulinemia de Waldenströn: comunicación de un caso. An Fac med. 2009;69(2):112-6.

16. Kyriakou P, Mouselimis D, Tsarouchas A, Rigopoulos A, Bakogiannis C, Noutsias M, et al. Diagnosis of cardiac amyloidosis: a systematic review on the role of imaging and biomarkers. BMC Cardiovasc Disord. 2018 Dec;18(1):221.

17. Jaccard A, Comenzo RL, Hari P, Hawkins PN, Roussel M, Morel P, et al. Efficacy of bortezomib , cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III ). Haematologica. Sept 2014;99(9):1479-85.

18. Mazzucchelli M, Frustaci AM, Deodato M, Cairoli R, Tedeschi A. Waldenstrom's Macroglobulinemia?: An Update. Mediterr J Hematol Infect Dis. 2018;88:1-18.

19. Paulus A, Manna A, Akhtar S, Paulus SM, Sharma M, Coignet MV, et al. Targeting CD38 with daratumumab is lethal to Waldenström macroglobulinaemia cells. Br J Haematol. 2018 Oct;183(2):196-211.